Ozempic Causes Blindness? Patients Sue GLP-1 Drugmakers Over Rare Eye Condition Risk
GLP-1 medicines have become increasingly popular for managing type 2 diabetes and, in some cases, obesity and weight management. But a new legal development in the US has put a rare eye condition and reports of sudden vision loss under the spotlight. According to a report by The Wall Street Journal, dozens of patients have filed lawsuits against the makers of popular GLP-1 medicines, alleging…
A growing number of patients are suing the manufacturers of popular GLP-1 medicines, alleging that the drugs caused sudden and possibly permanent vision loss. The lawsuits involve well-known medications like Ozempic and Wegovy from Novo Nordisk, and Zepbound from Eli Lilly. The alleged condition is nonarteritic anterior ischemic optic neuropathy, or NAION, a rare eye ailment that can lead to sudden loss of vision, usually affecting only one eye.
NAION is the central issue in these recent legal actions. The lawsuits don't prove that the GLP-1 medicines caused the injuries; they are mere allegations from individual patients. The relationship between these medications and NAION is still under investigation by researchers and regulators. Medical studies on the possible link between GLP-1 drugs and NAION are still inconclusive. This is crucial because a lawsuit is an allegation, not proof that a drug caused a specific medical condition.
While GLP-1 receptor agonists have become widely used in the past few years, primarily for type 2 diabetes and, in some cases, obesity and weight management, Novo Nordisk and Eli Lilly have both denied the allegations. The companies assert that the lawsuits are without merit.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
